Combivent and Fat tissue increased - a phase IV clinical study of FDA data

Summary:

Fat tissue increased is reported as a side effect among people who take Combivent (albuterol sulfate; ipratropium bromide), especially for people who are female, 50-59 old, also take Plaquenil, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Fat tissue increased when taking Combivent. It is created by eHealthMe based on reports of 35,104 people who have side effects when taking Combivent from the FDA, and is updated regularly.

What is Combivent?

Combivent has active ingredients of albuterol sulfate; ipratropium bromide. It is often used in asthma. eHealthMe is studying from 35,341 Combivent users. Check the latest studies of Combivent.

What is Fat tissue increased?

Fat tissue increased is found to be associated with 236 drugs and 337 conditions by eHealthMe. Check the latest studies of Fat tissue increased.

On Jul, 26, 2026

35,104 people reported to have side effects when taking Combivent.
Among them, 15 people (0.04%) have Fat tissue increased.

Could Combivent cause Fat tissue increased?

Among these 15 people:

What is the gender of people who have Fat tissue increased when taking Combivent? *

female: 93.33 %
male: 6.67 %

What is the age of people who have Fat tissue increased when taking Combivent? *

What are other drugs people take besides Combivent? *

What are other side effects people have besides Fat tissue increased? *

Swelling: 15 people, 100.00%
Weakness: 15 people, 100.00%
Pain In Extremity: 15 people, 100.00%
Muscle Spasms (muscle contraction): 15 people, 100.00%
Night Sweats (sweating in night): 14 people, 93.33%
Nodule (a growth of abnormal tissue): 14 people, 93.33%
Mouth Ulcers: 14 people, 93.33%
Bone Marrow Failure: 14 people, 93.33%
Oral Candidiasis (fungal infection of mouth): 14 people, 93.33%
Oral Pustule: 14 people, 93.33%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 14 people, 93.33%
Multiple Myeloma (cancer of the plasma cells): 14 people, 93.33%
Diabetes: 2 people, 13.33%
Up And Down Phenomenon: 1 person, 6.67%
Renal Disorder (kidney disease): 1 person, 6.67%
Pain In Extremity: 1 person, 6.67%
Muscle Aches (muscle pain): 1 person, 6.67%
Kidney Infection: 1 person, 6.67%
Dyspnea (difficult or laboured breathing): 1 person, 6.67%
Calcinosis (calcium deposits in any soft tissue): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Combivent and have Fat tissue increased?

- Check whether Fat tissue increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Combivent:

Combivent (35,341 reports)

Fat tissue increased treatments and more:

Fat tissue increased (2,886 reports)

How severe was Fat tissue increased and when was it recovered:

Fat tissue increased in Combivent

Expand to all the drugs that have ingredients of albuterol sulfate; ipratropium bromide:

Fat tissue increased and drugs with ingredients of albuterol sulfate; ipratropium bromide

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Combivent:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Fat tissue increased:

Fat tissue increased (237 drugs)

Browse all the conditions that are associated with Fat tissue increased:

Fat tissue increased (337 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on albuterol sulfate; ipratropium bromide (the active ingredients of Combivent) and Combivent (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.